| Popis: |
Introduction Hypercalcemia is a rare complication of myeloproliferative neoplasms. As a result, the underlying mechanisms and optimal treatment options remain under investigation. We present a case of hypercalcemia in post-essential thrombocythemia (ET) related myelofibrosis that was responsive to treatment with denosumab 60mg. Clinical Case A 65-year-old woman with ET for 10 years and recent progression to myelofibrosis (confirmed by bone marrow biopsy) was admitted for failure to thrive. Significant labs include: Ca 11.5 mg/dL (n: 8.5-10.5 mg/dL), corrected Ca 13.2 mg/dL, phosphorous 3.7 mg/dL (n: 2.4-4.7 mg/dL), PTH 5 pg/mL (n: 16-87 pg/mL), 25-OH Vitamin D 20.2 ng/mL (n: 30-100 ng/mL), 1,25 Vitamin D: 6.5 pg/mL (n: 19.9-79.3 pg/mL), PTHrP |
